Compare Icl Group Ltd (ICL) vs Eli Lilly And Co (LLY) Price & Performance

ICL trades at $5.00, down 0.99% over 24 hours, with a bearish technical signal. The company reported Q1 2026 earnings of $0.11 per share, beating estimates, and recently completed an $800 million senior notes offering. Revenue for 2025 was $7.15 billion with a net income margin of 3.15%, while valuation ratios show a P/E of 24.05 and P/S of 0.88. Analyst consensus is entirely hold-rated, reflecting cautious sentiment amid mixed financial trends.

The outlook for ICL is neutral with modest growth potential, supported by operational improvements and raised 2026 EBITDA guidance. Key risks include elevated raw material costs, foreign exchange headwinds, and competitive pressures in the specialty minerals sector. Investors should weigh stable cash flows against margin compression and debt levels from recent financing activities.

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.